Bladder cancer intrinsic LRFN2 drives anticancer immunotherapy resistance by attenuating CD8(+) T cell infiltration and functional transition

BACKGROUND: Immune checkpoint inhibitor (ICI) therapy improves the survival of patients with advanced bladder cancer (BLCA); however, its overall effectiveness is limited, and many patients still develop immunotherapy resistance. The leucine-rich repeat and fibronectin type-III domain-containing pro...

Descripción completa

Detalles Bibliográficos
Autores principales: Yu, Anze, Hu, Jiao, Fu, Liangmin, Huang, Gaowei, Deng, Dingshan, Zhang, Mingxiao, Wang, Yinghan, Shu, Guannan, Jing, Lanyu, Li, Huihuang, Chen, Xu, Yang, Taowei, Wei, Jinhuan, Chen, Zhenhua, Zu, Xiongbing, Luo, Junhang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2023
Materias:
Immunotherapy Biomarkers
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10565151/
https://www.ncbi.nlm.nih.gov/pubmed/37802603
http://dx.doi.org/10.1136/jitc-2023-007230

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10565151/
https://www.ncbi.nlm.nih.gov/pubmed/37802603
http://dx.doi.org/10.1136/jitc-2023-007230

Ejemplares similares